Candel Therapeutics Inc (CADL)
6.31
+0.06
(+0.96%)
USD |
NASDAQ |
Jul 03, 16:00
Candel Therapeutics Research and Development Expense (TTM): 23.14M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 23.14M |
| December 31, 2023 | 24.51M |
| September 30, 2023 | 22.22M |
| June 30, 2023 | 21.75M |
| March 31, 2023 | 20.84M |
| December 31, 2022 | 20.79M |
| September 30, 2022 | 19.67M |
| Date | Value |
|---|---|
| June 30, 2022 | 19.56M |
| March 31, 2022 | 17.83M |
| December 31, 2021 | 15.16M |
| September 30, 2021 | 14.84M |
| June 30, 2021 | 11.39M |
| March 31, 2021 | 9.895M |
| December 31, 2020 | 8.763M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
8.763M
Minimum
Dec 2020
24.51M
Maximum
Dec 2023
17.88M
Average
19.61M
Median
Research and Development Expense (TTM) Benchmarks
| Allurion Technologies Inc | 25.57M |
| AngioDynamics Inc | 32.65M |
| Eliem Therapeutics Inc | 10.78M |
| Macrogenics Inc | 166.74M |
| GlycoMimetics Inc | 20.68M |